ScandiDos

ScandiDos is a Swedish medical technology company based in Uppsala that develops and sells measurement phantoms and quality-assurance systems for radiotherapy. Its products are used to verify treatment plans and dose delivery in cancer care, with sales handled directly in some markets and through distributors in others.

— ScandiDos
%
Radiotherapy quality assurance systems70% Hardware and software used to verify treatment plans and dose delivery in radiation therapy.
Measurement phantoms20% Physical phantom products used for calibration and verification in radiotherapy workflows.
Software and digital verification tools5% Software platforms that support treatment-plan analysis and QA workflows.
Service and support5% Installation, maintenance, training, and technical support for installed systems.

ScandiDos sells to hospitals, cancer centers, and radiotherapy clinics that need to verify treatment plans and dose...

  • Hospitals and cancer centersprimary

    Buy Delta4 systems and phantoms to verify radiotherapy plans and dose delivery before treatment.

  • Public healthcare providersprimary

    Purchase QA equipment for standardized cancer-treatment workflows and compliance needs.

  • Private clinicssecondary

    Buy verification systems to support precision radiotherapy and efficient patient throughput.

  • Distributors and channel partnerssecondary

    Resell ScandiDos products in markets where the company does not sell directly.

ScandiDos is headquartered in Uppsala, Sweden, and its development and support functions are centered there...

  • Head office and core R&D are in Uppsala, Sweden
  • Direct sales in the Nordics, France, and the United States
  • Local distributors cover roughly 40 other markets
  • Asia is an important growth region for radiotherapy investment
  • Western Europe and North America are more mature replacement markets

ScandiDos focuses on radiotherapy quality assurance products that support precise and safe cancer treatment, with...

01
Grow in Asiamedium-term

Asian radiotherapy markets still require new equipment and offer more expansion than mature Western markets.

02
Protect and renew the installed baseshort-term

Western Europe and North America are mature, so growth depends on replacement sales and customer retention.

03
Advance product developmentmedium-term

New products help the company stay relevant as radiotherapy techniques become more complex.

04
Preserve market access through approvals and partnersshort-term

Regulatory clearance and distributor coverage are essential to selling in multiple countries.

ScandiDos faces exposure to currency movements because much of its sales are invoiced in euros and U.S...

high

Foreign exchange volatility

Most sales are invoiced in euros and U.S. dollars, creating translation and transaction exposure.

Scope
Revenue and cash flow
Materiality
high
high

Key-person dependence

The company relies on specialized technical and regulatory staff in a niche medtech business.

Scope
Operations and product development
Materiality
high
high

Regulatory approval delays

Product registrations and renewals can take longer than planned in different countries.

Scope
Launch timing and revenue recognition
Materiality
high
high

Impairment of capitalized intangibles

Delta4 Insight and other development assets depend on future commercialization success.

Scope
Balance sheet valuation
Materiality
high
medium

Distributor and partner concentration

Sales in many markets depend on local distributors and industry partners.

Scope
Market access and sales continuity
Materiality
medium
Development intangible asset impairment
Could accelerate write-downs if sales targets are missed
Foreign exchange hedging
Can create gains/losses in other comprehensive income or P&L depending on hedge treatment
Revenue recognition timing
Quarterly revenue can shift with shipment and approval timing
Related-party transactions
Relevant for assessing transfer pricing and governance

: 11/08/2026